FLXN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FLXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Flexion Therapeutics's gross profit for the three months ended in Sep. 2021 was $17.6 Mil. Flexion Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2021 was $79.2 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Flexion Therapeutics's gross profit for the three months ended in Sep. 2021 was $17.6 Mil. Flexion Therapeutics's Revenue for the three months ended in Sep. 2021 was $21.3 Mil. Therefore, Flexion Therapeutics's Gross Margin % for the quarter that ended in Sep. 2021 was 82.52%.
Flexion Therapeutics had a gross margin of 82.52% for the quarter that ended in Sep. 2021 => Durable competitive advantage
During the past 10 years, the highest Gross Margin % of Flexion Therapeutics was 98.87%. The lowest was 67.43%. And the median was 81.93%.
The historical data trend for Flexion Therapeutics's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Flexion Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | |||||||||||
Gross Profit | Get a 7-Day Free Trial | - | 0.35 | 15.19 | 63.00 | 66.30 |
Flexion Therapeutics Quarterly Data | ||||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | |
Gross Profit | Get a 7-Day Free Trial | 18.53 | 19.95 | 18.50 | 23.20 | 17.60 |
For the Drug Manufacturers - Specialty & Generic subindustry, Flexion Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Flexion Therapeutics's Gross Profit distribution charts can be found below:
* The bar in red indicates where Flexion Therapeutics's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Flexion Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2020 is calculated as
Gross Profit (A: Dec. 2020 ) | = | Revenue | - | Cost of Goods Sold |
= | 85.552 | - | 19.249 | |
= | 66.3 |
Flexion Therapeutics's Gross Profit for the quarter that ended in Sep. 2021 is calculated as
Gross Profit (Q: Sep. 2021 ) | = | Revenue | - | Cost of Goods Sold |
= | 21.326 | - | 3.727 | |
= | 17.6 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $79.2 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Flexion Therapeutics's Gross Margin % for the quarter that ended in Sep. 2021 is calculated as
Gross Margin % (Q: Sep. 2021 ) | = | Gross Profit (Q: Sep. 2021 ) | / | Revenue (Q: Sep. 2021 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 17.6 | / | 21.326 | |
= | 82.52 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Flexion Therapeutics (NAS:FLXN) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Flexion Therapeutics had a gross margin of 82.52% for the quarter that ended in Sep. 2021 => Durable competitive advantage
Thank you for viewing the detailed overview of Flexion Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark S. Levine | officer: General Counsel | 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451 |
Kerry Wentworth | officer: Chief Regulatory Officer | AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421 |
Christina Willwerth | officer: Chief Strategy Officer | C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, SUITE 301 BURLINGTON MA 01803 |
David Arkowitz | officer: Chief Financial Officer | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Melissa Layman | officer: Chief Commercial Officer | C/O FLEXION THERAPEUTICS, INC. 10 MALL ROAD, STE. 301 BURLINGTON MA 01803 |
Scott Kelley | officer: Chief Medical Officer | C/O ASPECT MEDICAL SYSTEMS INC 141 NEEDHAM ST NEWTON MA 02464-1505 |
Elizabeth Kwo | director | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Michael D. Clayman | director, officer: President and CEO | C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
Alan Milinazzo | director | C/O ORTHOFIX INC, 10115 KINCEY AVENUE STE 250, HUNTERSVILLE NC 28078 |
Scott A Canute | director | FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803 |
C Ann Merrifield | director | |
Heath Lukatch | director | 326 BOLLAY DRIVE, GOLETA CA 93117 |
Samuel D Colella | director, 10 percent owner | ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104 |
Patrick J Mahaffy | director | C/O CLOVIS ONCOLOGY, INC., 5500 FLATIRON PARKWAY, SUITE 100, BOULDER CO 80301 |
Mark Stejbach | director | C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 05-07-2021
By PRNewswire PRNewswire • 10-11-2021
By Marketwired Marketwired • 05-13-2021
By Marketwired Marketwired • 07-12-2021
By Marketwired Marketwired • 05-07-2021
By Marketwired Marketwired • 05-12-2021
By Marketwired Marketwired • 08-09-2021
By Marketwired Marketwired • 09-03-2021
By Marketwired Marketwired • 10-11-2021
By Marketwired Marketwired • 08-25-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.